Terms: = Prostate cancer AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769 AND Treatment
12 results:
1. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
2. A gata2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract] [Full Text] [Related]
3. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract] [Full Text] [Related]
4. Cellular rewiring in lethal prostate cancer: the architect of drug resistance.
Carceles-Cordon M; Kelly WK; Gomella L; Knudsen KE; Rodriguez-Bravo V; Domingo-Domenech J
Nat Rev Urol; 2020 May; 17(5):292-307. PubMed ID: 32203305
[TBL] [Abstract] [Full Text] [Related]
5. Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.
Copeland BT; Du J; Pal SK; Jones JO
Mol Oncol; 2019 Dec; 13(12):2616-2632. PubMed ID: 31520575
[TBL] [Abstract] [Full Text] [Related]
6. Molecular determinants for enzalutamide-induced transcription in prostate cancer.
Yuan F; Hankey W; Wu D; Wang H; Somarelli J; Armstrong AJ; Huang J; Chen Z; Wang Q
Nucleic Acids Res; 2019 Nov; 47(19):10104-10114. PubMed ID: 31501863
[TBL] [Abstract] [Full Text] [Related]
7. Androgen receptor transcriptionally regulates semaphorin 3C in a gata2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract] [Full Text] [Related]
8. gata2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.
He B; Lanz RB; Fiskus W; Geng C; Yi P; Hartig SM; Rajapakshe K; Shou J; Wei L; Shah SS; Foley C; Chew SA; Eedunuri VK; Bedoya DJ; Feng Q; Minami T; Mitsiades CS; Frolov A; Weigel NL; Hilsenbeck SG; Rosen DG; Palzkill T; Ittmann MM; Song Y; Coarfa C; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18261-6. PubMed ID: 25489091
[TBL] [Abstract] [Full Text] [Related]
9. gata2 as a potential metastasis-driving gene in prostate cancer.
Chiang YT; Wang K; Fazli L; Qi RZ; Gleave ME; Collins CC; Gout PW; Wang Y
Oncotarget; 2014 Jan; 5(2):451-61. PubMed ID: 24448395
[TBL] [Abstract] [Full Text] [Related]
10. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.
Andreu-Vieyra C; Lai J; Berman BP; Frenkel B; Jia L; Jones PA; Coetzee GA
Mol Cell Biol; 2011 Dec; 31(23):4648-62. PubMed ID: 21969603
[TBL] [Abstract] [Full Text] [Related]
11. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes.
Böhm M; Locke WJ; Sutherland RL; Kench JG; Henshall SM
Oncogene; 2009 Oct; 28(43):3847-56. PubMed ID: 19684615
[TBL] [Abstract] [Full Text] [Related]
12. ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity.
Hsu JY; Pfahl M
Cancer Res; 1998 Nov; 58(21):4817-22. PubMed ID: 9809984
[TBL] [Abstract] [Full Text] [Related]
